1. Home
  2. STOK vs SMBK Comparison

STOK vs SMBK Comparison

Compare STOK & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • SMBK
  • Stock Information
  • Founded
  • STOK 2014
  • SMBK N/A
  • Country
  • STOK United States
  • SMBK United States
  • Employees
  • STOK N/A
  • SMBK N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • SMBK Major Banks
  • Sector
  • STOK Health Care
  • SMBK Finance
  • Exchange
  • STOK Nasdaq
  • SMBK Nasdaq
  • Market Cap
  • STOK 638.8M
  • SMBK 553.9M
  • IPO Year
  • STOK 2019
  • SMBK N/A
  • Fundamental
  • Price
  • STOK $12.03
  • SMBK $35.41
  • Analyst Decision
  • STOK Strong Buy
  • SMBK Buy
  • Analyst Count
  • STOK 5
  • SMBK 5
  • Target Price
  • STOK $24.50
  • SMBK $34.40
  • AVG Volume (30 Days)
  • STOK 541.2K
  • SMBK 66.3K
  • Earning Date
  • STOK 08-06-2025
  • SMBK 07-21-2025
  • Dividend Yield
  • STOK N/A
  • SMBK 0.91%
  • EPS Growth
  • STOK N/A
  • SMBK 44.84
  • EPS
  • STOK 0.88
  • SMBK 2.26
  • Revenue
  • STOK $190,908,000.00
  • SMBK $171,664,000.00
  • Revenue This Year
  • STOK $378.84
  • SMBK $20.95
  • Revenue Next Year
  • STOK N/A
  • SMBK $9.48
  • P/E Ratio
  • STOK $13.80
  • SMBK $15.64
  • Revenue Growth
  • STOK 2333.81
  • SMBK 16.34
  • 52 Week Low
  • STOK $5.35
  • SMBK $23.26
  • 52 Week High
  • STOK $16.15
  • SMBK $37.72
  • Technical
  • Relative Strength Index (RSI)
  • STOK 67.00
  • SMBK 64.09
  • Support Level
  • STOK $11.19
  • SMBK $35.30
  • Resistance Level
  • STOK $12.00
  • SMBK $36.23
  • Average True Range (ATR)
  • STOK 0.54
  • SMBK 0.77
  • MACD
  • STOK -0.04
  • SMBK 0.24
  • Stochastic Oscillator
  • STOK 75.30
  • SMBK 74.30

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

Share on Social Networks: